TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

600329

CNE000001808

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-03-05			5-day change	1st Jan Change
41.00 ^CNY	+0.42%		-7.03%	-10.13%

Feb. 06	Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%	MT
Feb. 02	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Interim Dividend for the Financial Year Ended 31 December 2025, Payable on or About February 12, 2026	CI

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces the Cessation of Xie Xi as Supervisor

Published on 12/15/2025 at 05:23 am EST

S&P Capital IQ

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

+0.42%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced the cessation of Xie Xi as Supervisor. The cessation is due to the abolishment of the Supervisory Committee of the Company.

Latest news about Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Feb. 06	Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%	MT
Feb. 02	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Interim Dividend for the Financial Year Ended 31 December 2025, Payable on or About February 12, 2026	CI
Dec. 15	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces the Cessation of Guo Xiumei as Employee Supervisor	CI
Dec. 15	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces the Cessation of Xie Xi as Supervisor	CI
Dec. 15	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces the Cessation of Wang Yuanxi as Chairman of the Supervisory Committee	CI
Nov. 25	Tianjin Pharmaceutical Da Ren Tang Gets China Approval for Pain Relief Patch	MT
Nov. 25	Tianjin Pharmaceutical Da Ren Tang's Unit Granted Registration Certificate by Chinese Authority	MT
Nov. 25	Tianjin Pharmaceutical Plant Receives Drug Registration Certificate	CI
25-10-31	Tianjin Pharmaceutical Da Ren Tang Q3 Profit Up 54%, Revenue Down 38%	MT
25-10-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Proposes Interim Dividend for Fiscal Year 2025	CI
25-10-30	Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3	MT
25-08-14	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Soars in Q2	MT
25-08-14	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-14	Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1	MT

Chart Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Duration

Period

Chart Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

600329: Dynamic Chart

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.

Employees

4,619

Sector

Pharmaceuticals

Calendar

Mar. 31 - Earnings release - Annual 2025

More about the company